Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Pain 7Neoplasms 7Colonic Neoplasms 3Breast Neoplasms 3Rectal Neoplasms 2Pancreatic Neoplasms 2Cancer Pain 2Breakthrough Pain 2post laminectomy syndrome 1Waldenstrom Macroglobulinemia 1Vulvar Neoplasms 1Vipoma 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Thymoma 1Thrombocythemia, Essential 1Testicular Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Somatostatinoma 1Small Cell Lung Carcinoma 1Sezary Syndrome 1Sarcoma 1Salivary Gland Neoplasms 1Respiratory Insufficiency 1Prostatic Neoplasms 1Primary Myelofibrosis 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1

Interventions

Fentanyl 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Breakthrough Pain × Fentanyl × Clear all
NCT00263575 2024-06-18

Long-term Safety Study of Sublingual Fentanyl Tablets in Cancer Patients

Kyowa Kirin Co., Ltd.

Phase 3 Completed
139 enrolled 7 charts

Neoplasms, Pain, Breakthrough Pain

NCT00842829 2012-10-01

Study of Breakthrough Cancer Pain: Assessment of Fentanyl Buccal Tablets Titration and Treatment in Opioid-Tolerant Patients

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 4 Terminated
330 enrolled 32 charts

Cancer Pain, Breakthrough Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡